Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus

References

• Garcia MJ McNamara PM Gordon T Kannel WB Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study Diabetes 1974 23 2 105 111 4359625
   PubMed Web of Science ®Google Scholar
• Zilversmit DB Atherogenesis: a postprandial phenomenon Circulation 1979 60 3 473 485 222498
   PubMed Web of Science ®Google Scholar
• Ebenbichler CF Kirchmair R Egger C Patsch JR Postprandial state and atherosclerosis Curr Opin Lipidol 1995 6 5 286 290 8520851
   PubMed Web of Science ®Google Scholar
• Lefèbvre PJ Scheen AJ The postprandial state and risk of cardiovascular disease Diabet Med 1998 15 Suppl 4 S63 S68 9868996
   PubMed Web of Science ®Google Scholar
• Ceriello A The post-prandial state and cardiovascular disease: relevance to diabetes mellitus Diabetes Metab Res Rev 2000 16 2 125 132 10751752
   PubMed Web of Science ®Google Scholar
• Bonora E Muggeo M Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence Diabetologia 2001 44 12 2107 2114 11793012
   PubMed Web of Science ®Google Scholar
• Balkau B Shipley M Jarrett RJ High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study Diabetes Care 1998 21 3 360 367 9540016
   PubMed Web of Science ®Google Scholar
• Glucose tolerance and mortality: comparison of WHO American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe Lancet 1999 354 9179 617 621 10466661
   PubMed Web of Science ®Google Scholar
• Chiasson JL Josse RG Gomis R Hanefeld M Karasik A Laakso M STOP-NIDDM Trial Research Group Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial JAMA 2003 290 4 486 494 12876091
   PubMed Web of Science ®Google Scholar
• Cheng AY Fantus IG Oral antihyperglycemic therapy for type 2 diabetes mellitus CMAJ 2005 172 2 213 226 15655244
   PubMed Web of Science ®Google Scholar
• Harada S Nomura M Nakaya Y Ito S Nateglinide with glibenclamide examination using the respiratory quotient (RQ) J Med Invest 2006 53 3–4 303 309 16953069
   PubMedGoogle Scholar
• Vichayanrat A Ploybutr S Tunlakit M Watanakejorn P Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients Diabetes Res Clin Pract 2002 55 2 99 103 11796175
   PubMed Web of Science ®Google Scholar
• Kawamori R Tajima N Iwamoto Y Kashiwagi A Shimamoto K Kaku K Voglibose Ph-3 Study Group Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance Lancet 2009 373 9675 1607 1614 19395079
   PubMed Web of Science ®Google Scholar
• Malaisse WJ Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients Expert Opin Pharmacother 2008 9 15 2691 2698 18803455
   PubMed Web of Science ®Google Scholar
• Gao X Mitiglinide Versus Nateglinide Comparison Study Group Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China J Int Med Res 2009 37 3 812 821 19589264
   PubMed Web of Science ®Google Scholar
• Konya H Miuchi M Konishi K Pleiotropic effects of mitiglinide in type 2 diabetes mellitus J Int Med Res 2009 37 6 1904 1912 20146890
   PubMed Web of Science ®Google Scholar
• Phillippe HM Wargo KA Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus Ann Pharmacother 2010 44 10 1615 1623 20841518
   PubMed Web of Science ®Google Scholar
• Abe M Okada K Maruyama T Maruyama N Matsumoto K Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis Expert Opin Pharmacother 2010 11 2 169 176 20025554
   PubMed Web of Science ®Google Scholar
• Katsuno T Wantanabe N Nagai E Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus J Diabetes Investig 2011 2 3 204 209
   Web of Science ®Google Scholar
• Inoue M Tighter control of postprandial hyperglycemia with mitiglinide/voglibose fixed-dose combination in Japanese patients with type 2 diabetes mellitus Expert Opin Pharmacother 2012 13 16 2257 2268 22994875
   PubMed Web of Science ®Google Scholar
• Pharmaceutical and Medical Devices Agency Deliberation Report 3 23 2011 (Voglibose/Mitiglinide Tablets). 2011
   Google Scholar
• Mogami H Shibata H Nobusawa R Inhibition of ATP-sensitive K+ channel by a non-sulfonylurea compound KAD-1229 in a pancreatic beta-cell line, MIN 6 cell Eur J Pharmacol 1994 269 3 293 298 7895769
   PubMed Web of Science ®Google Scholar
• Reimann F Proks P Ashcroft FM Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel Br J Pharmacol 2001 132 7 1542 1548 11264248
   PubMed Web of Science ®Google Scholar
• Mori Y Ojima K Fuujimori Y Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats Endocrine 2006 29 2 309 315 16785606
   PubMed Web of Science ®Google Scholar
• Toyoda Y Mizutani K Miwa I Increase in hepatic glucose metabolism by mitiglinide calcium dehydrate-induced translocation of glucokinase from the nuclear to the cytoplasm Prog Med 2008 28 1951 1958 Japanese
   Google Scholar
• GLUFAST® tablets [package insert] 10th edition Tokyo, Japan Kissei Pharmaceutical Co, Ltd 2012
   Google Scholar
• FASTIC® tablets [package insert] 24th edition Tokyo, Japan Mochida Pharmaceutical Co, Ltd 2012
   Google Scholar
• SUREPOST® tablets [package insert] 4th edition Osaka, Japan Dainippon Sumitomo Pharma Co, Ltd 2013
   Google Scholar
• Sunaga Y Gonoi T Shibasaki T The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide Eur J Pharmacol 2001 431 1 119 125 11716850
   PubMed Web of Science ®Google Scholar
• Ohnota H Koizumi T Tsutsumi N Kobayashi M Inoue S Sato F Novel rapid- and short-acting hypoglycemic agent, a calcium(2 s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide J Pharmacol Exp Ther 1994 269 2 489 495 8182516
   PubMed Web of Science ®Google Scholar
• Assaloni R Da Ros R Quagliaro L Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients Diabetologia 2005 48 9 1919 1924 16007412
   PubMed Web of Science ®Google Scholar
• Thisted H Johnsen SP Rungby J Sulfonylureas and the risk of myocardial infarction Metabolism 2006 55 5 Suppl 1 S16 S19 16631805
   PubMed Web of Science ®Google Scholar
• Quast U Stephan D Bieger S Russ U The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium Diabetes 2004 53 Suppl 3 S156 S164 15561904
   PubMed Web of Science ®Google Scholar
• Abdelmoneim AS Hasenbank SE Seubert JM Brocks DR Light PE Simpson SH Variations in tissue selectivity amongst insulin secretagogues: a systematic review Diabetes Obes Metab 2012 14 2 130 138 21923736
   PubMed Web of Science ®Google Scholar
• Ogawa K Ikewaki K Taniguchi I Mitiglinide, a novel oral hypoglycemic agent, preserves the cardioprotective effect of ischemic preconditioning in isolated perfused rat hearts Int Heart J 2007 48 3 337 345 17592198
   PubMed Web of Science ®Google Scholar
• Maruyama I Tomiyama Y Maruyama K Effects of mitiglinide and sulfonylureas in isolated canine coronary arteries and perfused rat hearts Eur J Pharmacol 2006 531 1–3 194 200 16443212
   PubMed Web of Science ®Google Scholar
• Kato T Inoue T Node K Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study Cardiovasc Diabetol 2010 9 12 20334663
   PubMed Web of Science ®Google Scholar
• Yamaoka-Tojo M Tojo T Izumi T Beyond cholesterol lowering: pleiotropic effects of bile acid binding resins against cardiovascular disease risk factors in patients with metabolic syndrome Curr Vasc Pharmacol 2008 6 4 271 281 18855715
   PubMed Web of Science ®Google Scholar
• Yamaoka-Tojo M Tojo T Kosugi R Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia Lipids Health Dis 2009 8 41 19821987
   PubMed Web of Science ®Google Scholar
• Kitasato L Tojo T Hatakeyama Y Kameda R Hashikata T Yamaoka-Tojo M Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide Cardiovasc Diabetol 2012 11 79 22748110
   PubMed Web of Science ®Google Scholar
• Kamitani M Konya H Miuchi M Effects of mitiglinide on incretin hormone responses in a case of impaired glucose tolerance following total gastrectomy with Roux en Y rebuilding J Diabetes Invest 2012 3 Suppl 1 S237
   Google Scholar
• Kim W Egan JM The role of incretins in glucose homeostasis and diabetes treatment Pharmacol Rev 2008 60 4 470 512 19074620
   PubMed Web of Science ®Google Scholar
• Ono Y Kameda H Cho KY Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus Expert Opin Pharmacother 2013 14 4 361 370 23414242
   PubMed Web of Science ®Google Scholar
• Moritoh Y Takeuchi K Hazama M Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice J Pharmacol Exp Ther 2009 329 2 669 676 19208898
   PubMed Web of Science ®Google Scholar
• Cani PD Hoste S Guiot Y Delzenne NM Dietary non-digestible carbohydrates promote L-cell differentiation in the proximal colon of rats Br J Nutr 2007 98 1 32 37 17367575
   PubMed Web of Science ®Google Scholar
• Kosaka K Hagura R Kuzuya T Insulin responses in equivocal and definite diabetes, with special reference to subjects who had mild glucose intolerance but later developed definite diabetes Diabetes 1977 26 10 944 952 908463
   PubMed Web of Science ®Google Scholar
• Mitsui R Fukushima M Nishi Y Factors responsible for deteriorating glucose tolerance in newly diagnosed type 2 diabetes in Japanese men Metab Clin Exp 2006 55 1 53 58 16324919
   PubMed Web of Science ®Google Scholar
• Kadowaki T Miyake Y Hagura R Risk factors for worsening to diabetes in subjects with impaired glucose tolerance Diabetologia 1984 26 1 44 49 6368299
   PubMed Web of Science ®Google Scholar
• Abe M Okada K Soma M Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice Curr Drug Metab 2011 12 1 57 69 21303332
   PubMed Web of Science ®Google Scholar
• Abe M Okada K Maruyama T Maruyama N Matsumoto K Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis Endocr J 2010 57 7 579 586 20467165
   PubMed Web of Science ®Google Scholar
• Tschöpe D Bramlage P Binz C Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients – an analysis of the DiaRegis registry Cardiovasc Diabetol 2011 10 66 21756359
   PubMed Web of Science ®Google Scholar
• Ito M Abe M Okada K The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis Endocr J 2011 58 11 979 987 21921362
   PubMed Web of Science ®Google Scholar